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Malignant neuroendocrine tumour of the appendix is a
rare finding in the paediatric population. Metastases to
the loco-regional lymph nodes at time of diagnosis are
very rare. The literature reviewing the treatment and fol-
low up of such cases is not definitive regarding best
practice and management guidelines vary due to the
complexity and rarity of these tumours.Case presentation
A twelve year old girl presented acutely to the emer-
gency department, with a two day history of right iliac
fossa pain associated with nausea and vomiting. No fe-
vers or rigors were reported. The patient denied urinary
symptoms and was pre-menstrual. She had a back-
ground of recurrent presentations to the emergency de-
partment with non specific abdominal pain in the
preceding months. This girl had also been investigated
by the paediatric service regarding episodes of dizziness,
headaches and recurrent epistaxis. All previous investi-
gations were normal. On this occasion, she had tender-
ness, localised guarding and rebound in the right iliac
fossa. Her inflammatory markers were elevated, white
cell count (WCC) 14.2 and a C reactive protein (CRP) of
23.4. Intravenous antibiotics were commenced and a
plan for surgical intervention was made.* Correspondence: rebeccalyons@rcsi.ie
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unless otherwise stated.The patient underwent an emergency uncomplicated
laparoscopic appendicectomy. At the time of surgery, it
was noted that the apex of the appendix was distended.
(Figure 1) There were no signs of acute inflammation or
purulent fluid. The base of the appendix was ligated
using endoloops and the specimen was submitted for
histology. The patient made an uncomplicated recovery
and was discharged forty eight hours later.
Pathological examination of the appendix (measuring
60 mm in length) demonstrated a rare case of infiltrating
neuroendocrine tumour of the appendix. The tumour
penetrated the mucosa, submucosa and muscularis pro-
pria with extraluminal extenstion into the mesoappen-
dix. This tumour was well differentiated measuring
25 mm in maximal diameter. The tumour stained posi-
tive for chromogranin, CD 56 and synaptophysin. The
Ki67 proliferative index measured 15%, therefore con-
sistent with a Grade 2 (G2) neuroendocrine tumour. A
microscopic lymph node of the mesoappendix was also
analysed which stained positive for chromogranin A,
confirming a small metastatic deposit in the centre of
the lymph node. (Figure 2) The provisional staging of
pT3, N1 Mx was assigned and the patient proceeded to
staging investigations. A computerised tomography (CT)
scan of the thorax, abdomen and pelvis was performed
demonstrating a cluster of sub-centimetre lymph nodes
in the right paracolic gutter of indeterminate signifi-
cance. (Figure 3) Urinary 5 HIAA testing was also com-
pleted and a normal level reported.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Intra-operative image of the appendix at initial operation. Figure 3 CT scan identifying the sub centimetre lymph nodes in right
paracolic gutter.
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meeting, the decision to perform a laparoscopic right
hemicolectomy was made. The pathological examination
of the subsequent right hemicolectomy specimen showed
no evidence of residual tumour grossly or microscopically.
Forty seven loco-regional lymph nodes were retrieved.
Two of these lymph nodes were positive for metastatic
neuroendocrine tumour. These were located at 1 cm and
5 cm from the appendicectomy site. All peri-ileal lymph
nodes were free of disease. The immunohistochemistryFigure 2 Highlights the histological appendix specimen with staining. A: B
node. B: Neuroendocrine carcinoma of the appendix located at the apex w
neuroendocrine marker positive. D: Mesoappendiceal lymph node showinprofile again was positive for chromogranin, synaptophy-
sin and CD 56. (Figure 4).
The patient is currently doing well and has been
enrolled on a clinical and magnetic resonance imaging
(MRI) surveillance programme.
Conclusions
Laparoscopic appendicectomy is a common procedure in
the paediatric age group. Rarely has an unexpected diag-
nosis of a malignant neuroendocrine tumour of thease of the appendix with accompanying mesoappendiceal lymph
ith extramural extension into the mesoappendix. C: Chromogranin A,
g small focus of metastatic tumour.
Figure 4 Shows the histological lymph node specimen with staining. A and B: Large lymph node from right hemicolectomy specimen showing
metastatic tumour. C and D: Immuno staining positive for chromogranin A (C) and synaptophysin (D).
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tumours are the most common tumour of the gastrointes-
tinal tract in children, however malignant neuroendocrine
tumours are rare [1]. Table 1 highlights the key publica-
tions on malignant neuroendocrine tumours within the
paediatric population. Definitive incidence reporting
across the literature is lacking, with varying incidences be-
ing reported. However, Parkes et al. [2] has been refer-
enced widely in the literature with an incidence of 1.14
per million children. The other large study by Boxberger
et al. concluded that the incidence was 1 per 100,000 chil-
dren, a value that is widely referenced in the literature.
Up to 90% are diagnosed incidentally after laparo-
scopic appendicectomy [1]. Usually there is a large fe-
male predominance [3]. This is interesting, when one
considers the recent trend in the literature looking atTable 1 Highlights the incidence of malignant neuroendocrin
Author Number of child
Parkes et al. 1993 [2] 40 children over
Pelizzo et al. 2001 [1] 10 children over
D’Aleo et al. 2001 [15] 2 children
O’Donnell et al. 2006 [13] 3 children over 9
Boxberger et al. 2013 [3] 237 children ovethe conservative management of acute appendicitis in
children [4].
The presenting features of both benign and malignant
neuroendocrine tumours usually follow that of acute ap-
pendicitis as highlighted in our case. The well described
carcinoid syndrome of flushing, diarrhoea and cardiac
disease is rarely reported within the paediatric popula-
tion as this is associated with liver or retroperitoneal
metastases. It is in such cases that the 5 hydroxyindolea-
cetic acid (5HIAA) testing is positive [1,3,5,6].
Boxberger et. al studied neuroendocrine tumours in
children over a five year period. They noted that mean
age of presentation was 13 yrs (4.5-19.5), the majority of
those presented with signs of acute appendicitis and the
diagnosis was made histologically. The location of the
tumour similar to our case primarily was at the apex ofe tumours in the literature
ren in series Incidence reported
24 years 1.14 per million children
8 years 1.14 per million children
1 per 100,000 children
years 1 per 100,000 children
r 5 years 1 per 100,000 children
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dix in 63%. Extension into the mesoappendix was more
likely if the size of the primary tumour was over 15 mm.
It has been confirmed across the literature that site,
size and grade are significant in predicting aggressive be-
haviour of tumours [1,7]. Prognosis has been found to
be directly related to tumour size. Rossi et al. questioned
whether or not mesoappendiceal involvement was an in-
dicator or poor prognosis, however their study con-
firmed previous studies findings, that size is the main
determinant of prognosis [8,9,10].
Decision on further operative treatment after histo-
logical confirmation of malignant neuroendocrine tu-
mours is based on the size of the tumour. If the tumour
is less than 2 cm appendicectomy alone is the operation
of choice. A low proliferative index, an apical location of
the tumour, and lack of angiolymphatic or mesoappendi-
ceal invasion are other factors that influence surgery. A
right hemicolectomy is the operation of choice if the
tumour is greater than 2 cm, or if there is histological
evidence of mesoappendiceal extension or location of
the tumour at the base with caecal extension. However
it must be noted that only 20% of resected specimens
will show any residual disease.
The World Health Organisation revised the classifica-
tion system for neuroendocrine tumours in 2010 and
places considerable emphasis on the Ki67 proliferative
index. The Ki67 index is used to subdivide the neuroen-
docrine tumours into G1 or G2 neoplasms. If the Ki67
index is less than 3%, these are classified as G1. A Ki67
index between 3-20% classifies the tumours as G2. G3 is
represented by a Ki67 greater than 20%. Ki67% has been
studied as a factor for predicting metastases or recur-
rence. In 2013 Yamaguchi et. al investigated Ki67 as a
predictive index of tumour spread. This important study
reported that a Ki67 index of 2.8% or greater gave a spe-
cificity of 86.8% of having metastases or recurrence [11].
When assessing Ki67 as a marker for the biologic behav-
iour of tumours, it must be considered that Ki67 expres-
sion varies during the disease progression. This is not
fully understood at present, but literature available sug-
gests that Ki67 expression does vary and depending on
the time of measurement, Ki67 can result in the WHO
classification being upgraded. This has significant impli-
cations for treatment and follow up of these patients [12].
The presence of lymph node involvement as in our case,
is rare and has been reported sporadically in 4-5% of
paediatric cases [13,6]. A review of 414 cases looking at
neuroendocrine tumour and metastases found that only
4.1% of the cases had metastases identified. MacGillivary
et. al confirmed that tumours greater than 2 cm and
mesoappendiceal invasion are associated with metastatic
disease [6,14]. D’Aleo et. al suggested that a right hemi-
colectomy for a child with a neuroendocrine tumour ofthe appendix is a radical procedure as the prognosis is
quite good. 5 year survival is reported between 90-100%.
There is a trend towards limited resection as an alternative
option to the classic right hemicolectomy, with perhaps
an ileocaecal resection deemed appropriate [1].
No definitive follow up has been quoted in the litera-
ture. Despite the incidence of recurrent disease being
low, follow up is recommended. In general terms clinical
follow up, including chromogranin A (CgA) and 5 HIAA
testing is recommended. No studies have assessed the
sensitivity of these biologic markers to detect metastases
or local recurrence [3,15,16]. The ENETS guidelines rec-
ommend that if the tumour is less than 1 cm then no
specific follow up is needed. However if there is involve-
ment of lymph nodes, long term follow up is recom-
mended. MRI or CT is recommended in cases where the
initial tumour is greater than 2 cm, local invasion or
metastatic disease are present at diagnosis. MRI should
be considered in the young and in females of childbear-
ing age due to the lower radiation doses when compared
to serial CT scanning. It is recommended that these high
risk patients are followed up at 6 months and 12 months
post operatively and annually thereafter.Consent
Consent was obtained from the patient for publication.
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